These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 12811114)

  • 21. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
    Morgan SG; Li W; Yau B; Persaud N
    CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health policy implications of outcomes measurement in orthopaedics.
    Andrawis JP; Chenok KE; Bozic KJ
    Clin Orthop Relat Res; 2013 Nov; 471(11):3475-81. PubMed ID: 23625577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Copayment policy effects on healthcare spending and utilization by Korean lung cancer patients at end of life: a retrospective cohort design 2003-2012.
    Kim SJ; Han KT; Park EC; Park S; Kim TH
    Asian Pac J Cancer Prev; 2014; 15(13):5265-70. PubMed ID: 25040986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Policy Framework for Health Systems to Promote Triple Aim Innovation.
    Verma A; Bhatia S
    Healthc Pap; 2016; 15(3):9-23. PubMed ID: 27009582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient health management: a promising paradigm in Canadian healthcare.
    Montague T; Sidel J; Erhardt B; Nakhlé G; Caron L; Croteau D; Kader M; Haket J; Skilton K; McLeod B
    Am J Manag Care; 1997 Aug; 3(8):1175-82. PubMed ID: 10170300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges to achieving value in drug spending in a decentralized country: the Spanish case.
    Antoñanzas F
    Value Health; 2003; 6 Suppl 1():S52-63. PubMed ID: 12846926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. China's new policy for healthcare cost-control based on global budget: a survey of 110 clinicians in hospitals.
    Yan J; Lin HH; Zhao D; Hu Y; Shao R
    BMC Health Serv Res; 2019 Feb; 19(1):84. PubMed ID: 30709374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of cost and utilization of pharmaceuticals in Germany.
    von der Schulenburg JM
    Health Policy; 1997 Sep; 41 Suppl():S45-53. PubMed ID: 10174473
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Healthcare system performance indicators: a new beginning for a reformed Canadian healthcare system.
    DeRosario JM
    J Healthc Qual; 1999; 21(1):37-41. PubMed ID: 10351220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Primer on Population Health Management and Its Perioperative Application.
    Boudreaux AM; Vetter TR
    Anesth Analg; 2016 Jul; 123(1):63-70. PubMed ID: 27152835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The drug budget silo mentality: the French case.
    Le Pen C
    Value Health; 2003; 6 Suppl 1():S10-9. PubMed ID: 12846922
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost and cost-effectiveness of PPIs--GP perspectives and responses to a prescribing dilemma and their implications for the development of patient-centred healthcare.
    Pollock K; Grime J
    Eur J Gen Pract; 2003 Dec; 9(4):126-33, 140. PubMed ID: 14733400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources.
    Ruof J; Hülsemann JL; Mittendorf T; Handelmann S; von der Schulenburg JM; Zeidler H; Merkesdal S
    Ann Rheum Dis; 2003 Jun; 62(6):544-9. PubMed ID: 12759292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Medicaid prescription drug coverage: state efforts to control costs.
    Gencarelli DM
    NHPF Issue Brief; 2003 May; (790):1-17. PubMed ID: 12751504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of a price cut reform on the cost and utilization of antidiabetic drugs in Korea: a national health insurance database study.
    Suh HS; Kim JA; Lee IH
    BMC Health Serv Res; 2018 Jun; 18(1):429. PubMed ID: 29879966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The drug budget silo mentality: the Dutch case.
    Koopmanschap MA; Rutten FF
    Value Health; 2003; 6 Suppl 1():S46-51. PubMed ID: 12846925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Impact of China's National Essential Medicine Policy and Its Implications for Urban Outpatients: A Multivariate Difference-in-Differences Study.
    Ding L; Wu J
    Value Health; 2017 Mar; 20(3):412-419. PubMed ID: 28292486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Demand-side policies to encourage the use of generic medicines: an overview.
    Dylst P; Vulto A; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2013 Feb; 13(1):59-72. PubMed ID: 23402447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spending on pharmaceuticals in Italy: macro constraints with local autonomy.
    Mapelli V; Lucioni C
    Value Health; 2003; 6 Suppl 1():S31-45. PubMed ID: 12846924
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Delivering affordable cancer care in high-income countries.
    Sullivan R; Peppercorn J; Sikora K; Zalcberg J; Meropol NJ; Amir E; Khayat D; Boyle P; Autier P; Tannock IF; Fojo T; Siderov J; Williamson S; Camporesi S; McVie JG; Purushotham AD; Naredi P; Eggermont A; Brennan MF; Steinberg ML; De Ridder M; McCloskey SA; Verellen D; Roberts T; Storme G; Hicks RJ; Ell PJ; Hirsch BR; Carbone DP; Schulman KA; Catchpole P; Taylor D; Geissler J; Brinker NG; Meltzer D; Kerr D; Aapro M
    Lancet Oncol; 2011 Sep; 12(10):933-80. PubMed ID: 21958503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.